BD (NYSE:BDX) announced today that it completed the acquisition of flow cytometry solution developer Cytognos.
Salamanca, Spain-based Cytognos specializes in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases.
Franklin Lakes, New Jersey-based BD said in a news release that the acquisition accelerates its strategy to support chronic disease management by expanding its portfolio of blood cancer diagnostics, immune assessment tests and informatics to better understand the immune system, immune response and MRD.
The company said monitoring for MRD offers lab managers and physicians a way to detect low levels of cancer cells after treatment to demonstrate if the disease is still present or if there is a signal of recurrence.
“As the understanding and treatment of cancer evolves and improves, the importance of monitoring post remission cancer survivors has…